T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo.
Laurence A. Turka(Harvard University), David Gordon(Universidade Federal de Ouro Preto), Peter S. Linsley(Rosetta Stone (United States)), M L Gibson(University of Michigan), Sigrid E. Myrdal(University of British Columbia), Ru Wei(Broad Institute), Xiao-Zhi Zheng(University of Michigan), Jeffrey M. Leiden(Bluebird Bio (United States)), H. Lin(University of Michigan), William Brady(Bristol-Myers Squibb (United States))
Cited by 540
Related Papers
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease
|Science|2006|5.5k
<i>Consed:</i> A Graphical Tool for Sequence Finishing
|Genome Research|1998|3.3k
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
|New England Journal of Medicine|2005|2k
CTLA-4 is a second receptor for the B cell activation antigen B7.
|The Journal of Experimental Medicine|1991|1.7k
Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
|New England Journal of Medicine|2018|1.6k